Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus

Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript

XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment  in X-TOLE2 expected in late 2024 to early 2025

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

argenx

Intra-Cellular Therapies

Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet

Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering price of $32.50 per common share, and the pre-funded warrants were offered at a price of $32.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $32.50 per common share and the pre-funded warrants are being offered at a price of $32.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,384,615 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 4, 2023 subject to customary closing conditions.

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement. All of the common shares and pre-funded warrants in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $33.75 million of common shares at the public offering price, less the underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

Biotech stock Xenon rocketed Monday, after its experimental epilepsy drug unexpectedly showed promise in depression treatment.

The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring

Xenon Pharma shares moved higher on Monday despite the Vancouver, British Columbia neurology-focused biopharmaceutical company reporting that its investigational therapeutic for major depressive disorder (MDD) failed to meet the primary endpoint of a Phase 2 study. The study evaluated the efficacy, safety and tolerability of 10 mg and 20 mg of XEN1101 in patients with MDD.

Xenon Pharma depression drug fails to meet study goal but analysts see positives

Shares of Xenon Pharmaceuticals Inc. XENE fell 1.6% premarket on Monday after the neurology-focused company released new data from a clinical trial of its lead asset, an experimental depression treatment.

Xenon Pharmaceuticals' stock falls as depression treatment has mixed results in clinical trial

Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study.

Canada's Xenon Pharma's depression drug fails to meet main goal in study

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of Efficacy Data The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintains strong liquidity and cash runway. Market sentiment is cautiously optimistic, balancing XEN1101's clinical potential with financial challenges and competitive landscape.

Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James Tim Lugo - William Blair Operator Hello, thank you for standing by. And welcome to Xenon Pharmaceuticals Incorporated Third Quarter 2023 Earnings Conference Call.

Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder  on track for late November to mid-December

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals appears undervalued heading into a pivotal phase two MDD trial readout due by the end of November. If XEN-1101 shows either a trend towards improvement or hits the primary endpoint, then it would translate into a massive boon for its sales potential in treating epilepsy. I would assign the stock a buy rating, with a $51 price target, based off on modest assumptions.

News for Xenon Pharmaceuticals Stock (XENE)